Healthy Clinical Trial
Official title:
Fully Automated High-Throughput Quantitative MRI of the Liver
The purpose of this research is to see if a new automated magnetic resonance imaging (MRI) method will be able to improve the images taken of the liver. Participants will have either known or suspected liver disease, known or suspected iron overload syndrome, or be a healthy adult. Participants will be in the research study for one day.
Status | Recruiting |
Enrollment | 190 |
Est. completion date | September 2026 |
Est. primary completion date | September 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 7 Years and older |
Eligibility | Eligibility Criteria for Substudies 1, 2, 4, 5 Inclusion Criteria: - Age 18 years or older Exclusion Criteria: - Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc) - Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) Eligibility Criteria for Substudy 3 Inclusion Criteria: - Age 7 years or older - One of: - Known or suspected liver iron overload - Known or suspected elevated liver fat Exclusion Criteria: - Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc) - Sedation required for MRI - Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) Eligibility Criteria for Substudy 6 Inclusion Criteria: - Age 7 years or older - Scheduled for a clinical abdominal MRI exam Exclusion Criteria: - Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc) - Sedation required for MRI - Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | National Institute for Biomedical Imaging and Bioengineering (NIBIB) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Confirm the accuracy (ie: bias) of the proposed CSE-MRI method in patients with liver steatosis and in patients with liver iron overload | For each liver segment, and for whole-liver PDFF and R2* measurements, we will determine bias of CSE 2D using CSE 3D BH as the reference from Bland-Altman analysis.
The range of R2* values leading to reliable measurements of PDFF and R2* will be determined using a two-segment piecewise linear model with the change point estimated from the data. |
1 day (1 study visit, up to 3.5 hours) | |
Secondary | Image quality of free breathing 2D chemical shift encoded (CSE) method | Image quality for each acquisition will be evaluated by 3 radiologists, using a Likert scale between 0 (worst/non-diagnostic) and 3 (best) for criteria including: motion artifacts, spatial resolution, SNR (signal- to-noise ratio), and overall image quality. | 1 day (1 study visit, up to 3.5 hours) | |
Secondary | Measure the repeatability of the proposed CSE-MRI method in patients with liver steatosis and in patients with liver iron overload | To compare repeatability for various acquisition/reconstruction methods, we will calculate the squared difference between each pair of repeated PDFF / R2* measurements, and will model this value including the acquisition/reconstruction method as a covariate using Generalized Estimating Equations (GEE), with subject as a random factor to account for within-subject correlation. This analysis will be performed for all liver segments and whole-liver measurements. Further, the repeatability coefficient will also be assessed separately for each method. Bland-Altman plots will also be used to visualize the repeatability profile over the PDFF / R2* range. The automated vs manual PDFF / R2* measurements will be evaluated for each acquisition. | 1 day (1 study visit, up to 3.5 hours) | |
Secondary | Confirm the reproducibility of the proposed CSE-MRI method across field strengths | The reproducibility of the proposed method between 1.5T and 3T will be evaluated in two ways. First, at each field strength, PDFF and R2* will each be compared between FB FAM CSE and BH CSE 3D (as the reference), using Bland Altman analysis to assess the bias. Second, PDFF will be compared between 1.5T and 3T using Bland Altman analysis for each method, based on the expected field strength independence of PDFF. R2* will also be compared between 1.5T and 3T for each method, after converting to liver iron concentration (LIC, mg/g) using the 1.5T and 3T calibrations determined by our group, to compensate for the effect of field strength on R2*. In all comparisons, the reproducibility coefficient, and interclass correlation coefficient (ICC) with 95% confidence intervals will be calculated to quantify the degree of reproducibility. | 1 day (1 study visit, up to 3.5 hours) | |
Secondary | Technical success rate of the integrated single-button push, fully automated CSE-MRI protocol in < 5 minutes of MR room time | The technical success rate of the integrated single-button push, fully automated CSE-MRI exam will be determined through completion rate of the exam in less than 5 minutes, radiologist evaluation of image quality using a Likert scale, and accuracy of the automated analysis compared to manual evaluation. | 1 day (1 study visit, up to 3.5 hours) | |
Secondary | Mean and standard deviation of total two-door suite time for the single-push button exam | Throughput of the single-button push exam will be quantified by: throughput (subjects/hour), suite time per subject (mean, standard deviation, median, and quartiles) and suite time components (eg: room turnaround time, prescan/scan time for each series). | 1 day (1 study visit, up to 3.5 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |